**For Patients with Common Solid Cancers**

**EAQ161CD Available Through ECOG-ACRIN Cancer Research Group**

**Biomarker Testing in Common Solid Cancers:**

**An Assessment of Current Practices in Precision Oncology in the Community Setting**

---

**Patient Population**

See Section 3.0 for Complete Eligibility Details

**Identification of Survey Participants:** The 43 adult NCORP PIs and CCDR Leads will be sent an invitational e-mail with a personalized link to the rostering form on REDCap. If they are interested in participating (or are undecided), they will designate a responsible CCDR individual at the component and subcomponent level responsible for completing the screening questionnaire, which will determine component/subcomponent eligibility

**Eligibility Criteria for Study Population** (note: if there is no qualifying pathology site, the component/subcomponent is not eligible; if there is at least one qualifying pathology practice, the designated individual will complete the Biomarker Survey for each qualifying pathology practice)

- An onsite pathology practice is a lab that is financially administered and operated by an NCORP component or subcomponent; this excludes commercial reference laboratories (i.e., Quest/LabCorp). Participating components/subcomponents should provide services to adult oncology groups, have an informed individual who is willing to serve as a representative and gather information to complete the assessment times (i.e., pathology practice medical director, administrative director, or designee) AND meet at least one of the following:
  - A single onsite pathology lab (and its set of testing practices), may provide biomarker/pathology testing services to one or more components/subcomponents that use this pathology lab (this is one pathology practice and one unit of analysis)
  - Several onsite pathology labs may provide services to one NCORP component/subcomponent (i.e., a health system with several hospitals and each hospital has its own onsite pathology lab that follows its own set of testing practices (each lab will represent one unit of analysis))
  - More than one onsite pathology lab that uses a common set of testing practices (provides services to one or more NCORP component/subcomponents (this is one unit of analysis)

---

**Treatment Plan**

See Section 5.0 for Complete Methodology Plan Details

The study will be conducted via a self-administered web-based assessment and will focus on biomarker testing for solid tumors and common malignancies: breast, lung, colorectal and melanoma. It will be conducted as a self-reported assessment of testing practices

The designated responsible CCDR individual for each component/subcomponent with at least one qualifying pathology practice will:

- Print the Biomarker Survey from the REDCap system
- Contact knowledgeable individuals (i.e., pathology practice medical director, administrative director, and/or designees) to obtain responses
- Keep a log of all individuals contacted to complete the assessment
- Submit responses to the Biomarker Survey using their personalized REDCap link (note: reminders will be sent and the survey will be closed 10 weeks post email issue)

14 pathology practices for which the Biomarker Survey was completed are selected at random for a brief audit of the primary outcome

**Webinar:** The study team will lead an instructional webinar

**Questionnaires:**

- **Site Rostering Form:** queries whether a component/subcomponent is part of a larger practice group with a common administrative structure and the interest in participating in the study
- **Component/Subcomponent Screening:** queries name and contact info of the responsible CCDR individual, the presence of one or more onsite pathology labs/contact info of the pathology practice informant
- **Biomarker Survey:** queries biomarker testing practices and characteristics (see protocol for details)
- **Outcome Validation Survey:** administered only to those selected at random for outcome validation

---

**Online enrollment and data management will be completed via REDCap**

**NOTE:** This is a study of organizations and not human subjects research; it is IRB exempt

**Protocol Information**

ECOG-ACRIN Operations-Boston: 857-504-2900, [http://ecog-acrin.org](http://ecog-acrin.org) (Member Login)